Towards Healthcare
U.S. Oncology Drugs Market to Grow USD 246.85 Billion by 2034

U.S. Oncology Drugs Market Size & Future Scope 2025 - 2034 with Key Approvals

According to market projections, the U.S. oncology drugs sector is expected to grow from USD 95.69 billion in 2024 to USD 246.85 billion by 2034, reflecting a CAGR of 9.94%. The extensive research, scientific innovations, and the market penetration of several cancer-treating drugs drive the global expansion of the oncology field. The U.S. led the market owing to the aging population, advancements in targeted therapies, and drug innovations.

Content

  • Last Updated: 01 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The U.S. oncology drugs market holds a valuation of USD 105.2 billion as of 2025, and will expand to USD 246.85 billion by 2034, achieving a CAGR of 9.94% between 2024 and 2034.

The U.S. oncology drugs market includes five segments such as drug class, therapy type, indication, dosage form, and distribution channel.

The key players in the U.S. oncology drugs market include GSK, Novartis, Johnson & Johnson, Pfizer, etc.

Key trends include newly approved diagnostics and therapeutics, such as several cancer-treating drugs that are approved by the U.S. FDA.

FDA, American Association for Cancer Research, NCI, etc.
Any Questions